SOLESENCE, INC. — Director's Dealing 2022

Dec 20, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NANOPHASE TECHNOLOGIES Corp (NANX)
CIK: 0000883107
Period of Report: 2022-12-16

Reporting Person: WHITMORE R JANET (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-16	Common Stock	P	4600	$1.10	Acquired	1527942	Direct
2022-12-19	Common Stock	P	4850	$1.10	Acquired	1532792	Direct
2022-12-19	Common Stock	P	1338	$1.13	Acquired	1534130	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1523342	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Deferred Common Stock	$		Common Stock (20030)	20030	Direct
Common Stock (right to purchase)	$0.52	2024-02-13	Common Stock (10000)	10000	Direct
Common Stock (right to purchase)	$0.44	2025-02-18	Common Stock (9000)	9000	Direct
Common Stock (right to purchase)	$0.42	2026-02-23	Common Stock (8100)	8100	Direct
Common Stock (right to purchase)	$0.90	2026-11-17	Common Stock (2000)	2000	Direct
Common Stock (right to purchase)	$1.05	2026-11-17	Common Stock (2000)	2000	Direct
Common Stock (right to purchase)	$1.18	2026-11-17	Common Stock (2000)	2000	Direct
Common Stock (right to purchase)	$0.84	2026-11-17	Common Stock (2000)	2000	Direct
Common Stock (right to purchase)	$1.85	2026-11-17	Common Stock (2000)	2000	Direct
Common Stock (right to purchase)	$1.10	2026-11-17	Common Stock (2000)	2000	Direct
Common Stock (right to purchase)	$0.99	2026-11-17	Common Stock (2000)	2000	Direct
Common Stock (right to purchase)	$0.68	2027-02-21	Common Stock (10000)	10000	Direct
Common Stock (right to purchase)	$0.82	2028-05-23	Common Stock (10000)	10000	Direct
Common Stock (right to purchase)	$0.51	2029-05-22	Common Stock (10000)	10000	Direct
Common Stock (right to purchase)	$0.45	2027-06-18	Common Stock (20000)	20000	Direct
Common Stock (right to purchase)	$4.17	2028-12-28	Common Stock (20000)	20000	Direct

Footnotes

F1: Each share of deferred common stock represents a right to receive one share of common stock.

F2: The deferred common stock becomes payable upon the reporting person's termination of service as a director of the Company.

F3: Pursuant to such plan, the reporting person elected to defer receipt of such shares and receive a cumulative total of 20,030 shares of deferred common stock which will all be accounted for under the Company's Non-Employee Director Deferred Compensation Plan.

F4: Beginning on this date, subject to certain restrictions, the stock option vests in three equal annual installments.

F5: Subject to certain rights and restrictions, beginning on this date, options vest in three equal annual installments.

F6: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,000 were issued with an exercise price of $0.90, 2,000 were issued with an exercise price of $1.05, 2,000 were issued with an exercise price of $1.18, 2,000 were issued with an exercise price of $0.84, 2,000 were issued with an exercise price of $1.85, 2,000 were issued with an exercise price of $1.10, and 2,000 were issued with an exercise price of $0.99.